Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss
about
ACAT2 and human hepatic cholesterol metabolism: identification of important gender-related differences in normolipidemic, non-obese Chinese patientsA new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretionThe thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient miceModulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient MiceA new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport.Dynamics of hepatic and intestinal cholesterol and bile acid pathways: The impact of the animal model of estrogen deficiency and exercise trainingRole of the intestinal bile acid transporters in bile acid and drug dispositionThe serine hydrolase ABHD6 Is a critical regulator of the metabolic syndromeA reappraisal of the mechanism by which plant sterols promote neutral sterol loss in miceTG-interacting factor 1 acts as a transcriptional repressor of sterol O-acyltransferase 2.Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterolAcute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion.Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilizationBiliary sterol secretion is not required for macrophage reverse cholesterol transportCholesterol esters (CE) derived from hepatic sterol O-acyltransferase 2 (SOAT2) are associated with more atherosclerosis than CE from intestinal SOAT2Reverse cholesterol transport is elevated in carboxyl ester lipase-knockout miceHepatic ACAT2 knock down increases ABCA1 and modifies HDL metabolism in miceUncleaved ApoM signal peptide is required for formation of large ApoM/sphingosine 1-phosphate (S1P)-enriched HDL particles.Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis.Adipose-selective overexpression of ABHD5/CGI-58 does not increase lipolysis or protect against diet-induced obesity.CGI-58/ABHD5-derived signaling lipids regulate systemic inflammation and insulin action.Protein mediators of sterol transport across intestinal brush border membrane.Tissue-specific knockouts of ACAT2 reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood.Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.Trust your gut: galvanizing nutritional interest in intestinal cholesterol metabolism for protection against cardiovascular diseasesThe Impairment of Macrophage-to-Feces Reverse Cholesterol Transport during Inflammation Does Not Depend on Serum Amyloid A.Intestinal SR-BI does not impact cholesterol absorption or transintestinal cholesterol efflux in mice.Biliary and nonbiliary contributions to reverse cholesterol transport.Acyl-coenzyme A:cholesterol acyltransferases.Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol.Influence of class B scavenger receptors on cholesterol flux across the brush border membrane and intestinal absorption.Estrogen decreases atherosclerosis in part by reducing hepatic acyl-CoA:cholesterol acyltransferase 2 (ACAT2) in monkeys.Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein.Sterol O-Acyltransferase 2-Driven Cholesterol Esterification Opposes Liver X Receptor-Stimulated Fecal Neutral Sterol Loss.Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse.Reverse cholesterol transport: from classical view to new insights.Biliary cholesterol secretion: more than a simple ABC.From blood to gut: direct secretion of cholesterol via transintestinal cholesterol efflux.Intestinal nuclear receptors in HDL cholesterol metabolism.An integrated approach for the mechanisms responsible for atherosclerotic plaque regression
P2860
Q24649651-46F24AA9-732B-4DF7-BAC0-AE77D62E5F3AQ26865600-0A6FE6FA-214F-47F7-9DC3-E2FA0200336DQ27303091-14BD9805-F993-4FCF-9FAF-C1E5BD19901FQ27332357-200CF7E8-2D82-4465-8B8F-1EAD00156848Q27693251-9D896C53-698A-46A9-97A4-40C26A5F3554Q28073180-DE9BFAB3-66F0-417D-A445-5F21E078717CQ28299162-24EE0E14-D8F5-437A-B939-0B4A2750BD35Q28504726-B58B904A-E19F-43B9-966A-3B2F77F9F443Q28743016-357337E6-4578-4E2C-8D37-E6D214E833FBQ30406107-EB142856-8BD0-44EF-A58E-A8E1E9CD61D5Q33660599-0F07A383-D7E8-4202-B02A-3E1301592390Q33717139-119463A0-30ED-41D5-8F6D-949B3D2DDA6FQ33824907-C8F11E2C-0DC3-47E1-AF19-C170EC8643DAQ34035681-B0C8F5AA-8908-460D-B8C7-E511D6B0D5F9Q34403124-6518B0B5-23E2-4BEE-ABB9-2083EAFB9CF8Q34682311-13B829B5-2D9B-4807-AAF0-60AA9C00FE0DQ35138400-1A6FA80B-BA33-463F-9614-D677403CCB00Q35199447-FAD2D888-CC83-4A64-8215-991808A5975FQ35338937-D6ACBB55-2700-4989-9CCF-CBE5DBA75D34Q35380219-759C3B99-D236-48D6-8FDC-2CA9CB62FB87Q35696460-979223D2-D0F1-4671-BB8D-0DB34957D5A5Q35838266-D39D3B2A-8AB4-4139-86BF-AB6B179449A7Q35958460-FDF50676-3E18-421F-89A5-CE6B85C20B18Q36007212-366D1AF2-748D-4A66-869A-5C7A5727D053Q36607669-9520FA1A-677F-4BB0-B45A-2E4D72376B1DQ36610558-37C40461-A77B-4A7C-AA71-986699D51BF2Q36822555-A533B27C-08C2-4EB9-8B50-D0361B3D415EQ37013347-95770FA3-FD8F-4C0A-8E9B-1313A256F6FDQ37264194-95D9D8BA-5F17-40A2-8933-0639BF693D11Q37339259-6FCB1202-2AF2-4B03-AB35-C01A4962CBE2Q37382146-3BD83E7E-306A-40F5-B6BA-287DDB39B458Q37390344-CDF70945-F612-4FDF-8597-A94D14E0ECB5Q37536536-DEF8ADA0-1882-4CDF-B3F6-82A5D4660AEAQ37573558-D2A631E0-273E-402D-BBCE-68FF0776DCC5Q37707904-516D3942-0325-4A03-8C09-409701D28F6EQ37820949-09B35133-D015-4D23-A89F-B0407B8ECEC4Q37820950-6D728399-E647-4B56-BB3A-2D37D3F63BD6Q37820951-BA49F7E8-AABA-4094-A24D-8C626103D229Q38234847-2B681775-EB12-4EE9-846F-B923E14C61CDQ38963714-572379ED-7F0E-462A-A2B0-1D5A3FAE6CA5
P2860
Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Targeted depletion of hepatic ...... for fecal neutral sterol loss
@en
Targeted depletion of hepatic ...... for fecal neutral sterol loss.
@nl
type
label
Targeted depletion of hepatic ...... for fecal neutral sterol loss
@en
Targeted depletion of hepatic ...... for fecal neutral sterol loss.
@nl
prefLabel
Targeted depletion of hepatic ...... for fecal neutral sterol loss
@en
Targeted depletion of hepatic ...... for fecal neutral sterol loss.
@nl
P2093
P2860
P356
P1476
Targeted depletion of hepatic ...... for fecal neutral sterol loss
@en
P2093
Heather M Alger
J Mark Brown
Janet K Sawyer
Kathryn Kelley
Lawrence L Rudel
Mark J Graham
Martha D Wilson
Matthew A Davis
Ramesh Shah
Richard G Lee
P2860
P304
10522-10534
P356
10.1074/JBC.M707659200
P407
P577
2008-02-14T00:00:00Z